Lipid Nanovesicle Platforms for Hepatocellular Carcinoma Precision Medicine Therapeutics : Progress and Perspectives
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality globally. HCC is highly heterogenous with diverse etiologies leading to different driver mutations potentiating unique tumor immune microenvironments. Current therapeutic options, including immune checkpoint inhibitors and combinations, have achieved limited objective response rates for the majority of patients. Thus, a precision medicine approach is needed to tailor specific treatment options for molecular subsets of HCC patients. Lipid nanovesicle platforms, either liposome- (synthetic) or extracellular vesicle (natural)-derived present are improved drug delivery vehicles which may be modified to contain specific cargos for targeting specific tumor sites, with a natural affinity for liver with limited toxicity. This mini-review provides updates on the applications of novel lipid nanovesicle-based therapeutics for HCC precision medicine and the challenges associated with translating this therapeutic subclass from preclinical models to the clinic.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Organogenesis - 20(2024), 1 vom: 31. März, Seite 2313696 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lehrich, Brandon M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cell therapy |
|---|
| Anmerkungen: |
Date Completed 16.02.2024 Date Revised 23.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/15476278.2024.2313696 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368479110 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368479110 | ||
| 003 | DE-627 | ||
| 005 | 20240323235059.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240215s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/15476278.2024.2313696 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1342.xml |
| 035 | |a (DE-627)NLM368479110 | ||
| 035 | |a (NLM)38357804 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lehrich, Brandon M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lipid Nanovesicle Platforms for Hepatocellular Carcinoma Precision Medicine Therapeutics |b Progress and Perspectives |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.02.2024 | ||
| 500 | |a Date Revised 23.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality globally. HCC is highly heterogenous with diverse etiologies leading to different driver mutations potentiating unique tumor immune microenvironments. Current therapeutic options, including immune checkpoint inhibitors and combinations, have achieved limited objective response rates for the majority of patients. Thus, a precision medicine approach is needed to tailor specific treatment options for molecular subsets of HCC patients. Lipid nanovesicle platforms, either liposome- (synthetic) or extracellular vesicle (natural)-derived present are improved drug delivery vehicles which may be modified to contain specific cargos for targeting specific tumor sites, with a natural affinity for liver with limited toxicity. This mini-review provides updates on the applications of novel lipid nanovesicle-based therapeutics for HCC precision medicine and the challenges associated with translating this therapeutic subclass from preclinical models to the clinic | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cell therapy | |
| 650 | 4 | |a exosomes | |
| 650 | 4 | |a extracellular vesicles | |
| 650 | 4 | |a hepatocellular carcinoma | |
| 650 | 4 | |a lipid nanovesicles | |
| 650 | 4 | |a precision medicine | |
| 650 | 7 | |a Lipids |2 NLM | |
| 700 | 1 | |a Delgado, Evan R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Organogenesis |d 2004 |g 20(2024), 1 vom: 31. März, Seite 2313696 |w (DE-627)NLM183986377 |x 1555-8592 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2024 |g number:1 |g day:31 |g month:03 |g pages:2313696 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/15476278.2024.2313696 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2024 |e 1 |b 31 |c 03 |h 2313696 | ||